This case underscores the critical role of immune-mediated complications following CAR-T cell therapy, particularly the progression from CRS to IEC-HS, where macrophages and effector cells predominantly drive pathophysiology through the production of IFN-γ (2). The gene discussed is IFNG; the disease is congenital rubella syndrome.